Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21473206 | 1.00 | PTPN2 (0.35) | PTPN2PTPN1 | |
| SCHEMBL21473194 | 1.00 | PTPN2 (0.35) | PTPN2PTPN1 | |
| SCHEMBL21473199 | 1.00 | PTPN2 (0.35) | PTPN2PTPN1 | |
| SCHEMBL956269 | 1.00 | PTPN2 (0.35) | PTPN2PTPN1 | |
| SCHEMBL960104 | 0.87 | UGT2B7 (0.38) | — | |
| SCHEMBL960105 | 0.87 | UGT2B7 (0.38) | — | |
| SCHEMBL960500 | 0.77 | — | — | |
| SCHEMBL960498 | 0.77 | — | — | |
| SCHEMBL21504589 | 0.76 | — | — | |
| SCHEMBL20245300 | 0.73 | PTPN2 (0.48) | PTPN2PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260034186-A1 | ENRICHED MINERAL PITCH RESIN PRODUCTS AND METHODS OF MANUFACTURING ENRICHED MINERAL PITCH RESIN PRODUCTS | RIZUN NODARI (US) | 2026-02-05 | — | — | US | disclosed |
| US-20260027136-A1 | CANNABIS BASED THERAPEUTIC AND METHOD OF USE | YUZU LV LLC (US) | 2026-01-29 | — | — | US | disclosed |
| US-12458653-B2 | Cannabis based therapeutic and method of use | YUZU LV LLC (US) | 2025-11-04 | — | — | US | disclosed |
| US-12427176-B2 | Enriched mineral pitch resin products and methods of manufacturing enriched mineral pitch resin products | RIZUN NODARI (US) | 2025-09-30 | — | — | US | disclosed |
| US-12303488-B2 | Cannabis based therapeutic and method of use | YUZU LV LLC (US) | 2025-05-20 | — | — | US | disclosed |
| EP-4417252-A2 | CANNABIS BASED THERAPEUTIC AND METHOD OF USE | Yuzu LV LLC (US) | 2024-08-21 | — | — | EP | disclosed |
| US-20240216457-A1 | ENRICHED MINERAL PITCH RESIN PRODUCTS AND METHODS OF MANUFACTURING ENRICHED MINERAL PITCH RESIN PRODUCTS | RIZUN NODARI (US) | 2024-07-04 | — | — | US | disclosed |
| US-20240216456-A1 | ENRICHED MINERAL PITCH RESIN PRODUCTS AND METHODS OF MANUFACTURING ENRICHED MINERAL PITCH RESIN PRODUCTS | RIZUN NODARI (US) | 2024-07-04 | — | — | US | disclosed |
| US-20240207342-A1 | ENRICHED MINERAL PITCH RESIN PRODUCTS AND METHODS OF MANUFACTURING ENRICHED MINERAL PITCH RESIN PRODUCTS | RIZUN NODARI (US) | 2024-06-27 | — | — | US | disclosed |
| US-20240207344-A1 | ENRICHED MINERAL PITCH RESIN PRODUCTS AND METHODS OF MANUFACTURING ENRICHED MINERAL PITCH RESIN PRODUCTS | RIZUN NODARI (US) | 2024-06-27 | — | — | US | disclosed |
| US-8470889-B2 | Hybrid-ionone and curcumin molecules as anticancer agents | TRT PHARMA INC. (CA) | 2013-06-25 | — | — | US | disclosed |
| US-8470889-B2 | Hybrid-ionone and curcumin molecules as anticancer agents | TRT PHARMA INC. (CA) | 2013-06-25 | — | — | US | disclosed |
| EP-2442644-A1 | OPSIN-BINDING LIGANDS, COMPOSITIONS AND METHODS OF USE | Bikam Pharmaceuticals, Inc. (US) | 2012-04-25 | — | — | EP | disclosed |
| US-20110230488-A1 | HYBRID-IONONE AND CURCUMIN MOLECULES AS ANTICANCER AGENTS | TRT PHARMA INC. (CA) | 2011-09-22 | — | — | US | disclosed |
| US-20110230488-A1 | HYBRID-IONONE AND CURCUMIN MOLECULES AS ANTICANCER AGENTS | TRT PHARMA INC. (CA) | 2011-09-22 | — | — | US | disclosed |
| US-20110003784-A1 | Opsin-binding ligands, compositions and methods of use | BIKAM PHARMACEUTICALS INC. | 2011-01-06 | — | — | US | disclosed |
| WO-2010147653-A1 | OPSIN-BINDING LIGANDS, COMPOSITIONS AND METHODS OF USE | BIKAM PHARMACEUTICALS, INC. (US) | 2010-12-23 | — | — | WO | disclosed |
| WO-2010060214-A1 | HYBRID -IONONE AND CURCUMIN MOLECULES AS ANTICANCER AGENTS | TRT PHARMA INC . (CA) | 2010-06-03 | — | — | WO | disclosed |
| US-RE30260-E | 1-(2,6,6-Trimethyl-3-hydroxy-1-cyclohexen-1-yl)-3-methyl-penta-1,4-diene[or 1-yn-4-en]-3-ols | HOFFMANN-LA ROCHE INC. (US) | 1980-04-22 | — | — | US | disclosed |
| US-4098827-A | 1-(2,6,6-Trimethyl-3-hydroxy-1-cyclohexen-1-yl)-3-methyl-penta-1,4-diene[or 1-yn-4-EN]-3-ols | HOFFMANN-LA ROCHE INC. (US) | 1978-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230488-A1 | HYBRID-IONONE AND CURCUMIN MOLECULES AS ANTICANCER AGENTS | IKBKG, HSD17B11, IKBKE | PTPN2 4348/4885PTPN1 4363/4885 |
| US-20110003784-A1 | Opsin-binding ligands, compositions and methods of use | CRYAB, CRYAA, UACA | PTPN2 1993/4885PTPN1 1966/4885 |
| US-20260027136-A1 | CANNABIS BASED THERAPEUTIC AND METHOD OF USE | CNR1, CNR2, OPRM1 | PTPN2 2364/4885PTPN1 1893/4885 |
| US-20260034186-A1 | ENRICHED MINERAL PITCH RESIN PRODUCTS AND METHODS OF MANUFACTURING ENRICHED MINERAL PITCH RESIN PRODUCTS | TRPV1, SOST, RUNX1 | PTPN2 4037/4885PTPN1 4282/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.